Ahjin Lim

RAF1 extrachromosomal DNA amplification confers acquired erlotinib resistance in a non-small cell lung cancer cell model

Sujin Kim, Boyoon Kim, Ahjin Lim, Hoon Kim et autres

EGFR (epidermal growth factor receptor)-targeted therapies, which utilize small molecule inhibitors such as erlotinib and osimertinib to inhibit aberrantly activated EGF receptors caused by oncogenic mutations such as L858R and exon 19 deletion occurring primarily in the region coding its kinase domain, …

kr (code pays fourni par la source)

Figure 3 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

Yo Han Jeon, Ahjin Lim, Myung Kyung Choi, Hee Seong Choi et autres

The EGFR L833V/H835L mutant exhibits sensitivity to EGFR TKIs both in vitro and in vivo. A and B, NIH-3T3 (A) or Ba/F3 (B) cells expressing the indicated EGFR mutants were treated with erlotinib, afatinib, or osimertinib at the concentrations indicated for 6 …

Table S1 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

Yo Han Jeon, Ahjin Lim, Myung Kyung Choi, Hee Seong Choi et autres

Supplementary Table 1

Figure S2 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

Yo Han Jeon, Ahjin Lim, Myung Kyung Choi, Hee Seong Choi et autres

Figure S2. Purification profiles and in vitro kinase activity of WT and mutated EGFR kinases.

Data from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

Yo Han Jeon, Ahjin Lim, Myung Kyung Choi, Hee Seong Choi et autres

Abstract Non–small cell lung cancer (NSCLC) with EGFR L833V/H835L in cis mutation remains poorly understood. We retrospectively reviewed the clinicopathologic features of NSCLC with either EGFR L833V or H835L mutation. The study population includes patients with NSCLC (n = 3,835) at Samsung …

Figure S3 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

Yo Han Jeon, Ahjin Lim, Myung Kyung Choi, Hee Seong Choi et autres

Figure S3. Response of EGFR-TKI in xenograft mouse model

Figure S1 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

Yo Han Jeon, Ahjin Lim, Myung Kyung Choi, Hee Seong Choi et autres

Fig. S1. Mutational impact on EGFR kinase structure, R-spine alignment, and dimer interface

Figure 2 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

Yo Han Jeon, Ahjin Lim, Myung Kyung Choi, Hee Seong Choi et autres

The EGFR L833V/H835L mutant is oncogenic in vitro. A, NIH-3T3 cells encoding WT or mutant EGFR were assayed for anchorage-independent growth in soft agar with or without 25 ng/mL EGF stimulation. Representative photomicrographs of soft agar colonies from three independents results are …

Figure 1 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

Yo Han Jeon, Ahjin Lim, Myung Kyung Choi, Hee Seong Choi et autres

Detection of EGFR L833V/H835L in cis mutations and its histopathologic characteristics in the surgically resected NSCLC. A and B,EGFR c.2497T>G (p.Leu833Val) mutation and EGFR c.2504A>T (p.His835Leu) mutations presenting in cis were detected by NGS analysis (A) of the surgical specimen from patient …

Table 1 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

Yo Han Jeon, Ahjin Lim, Myung Kyung Choi, Hee Seong Choi et autres

Clinicopathologic features of the NSCLC harboring either EGFR L833V or H835L mutation.

Additional data_RAF1 extrachromosomal DNA amplification confers acquired erlotinib resistance in non-small cell lung cancer cell model

Sujin Kim, Boyoon kim, Ahjin Lim, Hoon Kim et autres

Fig. S1. EGFR gene status and Structural variant cluster and ecDNA-associated oncogene amplification and expression in ER-R (a) ER-R cells retained the sensitizing EGFR exon 19 deletion, with only additional silent mutations detected.(b) Reduced EGFR copy number and expression reflect the loss …

Additional data_RAF1 extrachromosomal DNA amplification confers acquired erlotinib resistance in non-small cell lung cancer cell model

Sujin Kim, Boyoon kim, Ahjin Lim, Hoon Kim et autres

Fig. S1. EGFR gene status and Structural variant cluster and ecDNA-associated oncogene amplification and expression in ER-R (a) ER-R cells retained the sensitizing EGFR exon 19 deletion, with only additional silent mutations detected.(b) Reduced EGFR copy number and expression reflect the loss …